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THE ROLE OF ESTROGEN RECEPTORS ALPHA AND BETA IN THE 
DEVELOPMENT OF UTERINE LEIOMYOMAS 
JACQUELINE KOOMSON 
ABSTRACT 
Uterine leiomyomas are benign tumors within the uterus, where patients present 
with symptoms such as abnormal bleeding, urinary retention, and pelvic 
pressure. The exact etiology of uterine leiomyomas is unknown, but numerous 
theories have been proposed, indicating a multifactorial mechanism, including 
lifestyle and steroid hormones. Uterine leiomyomas have become a public health 
concern due to the high cost of treatment as well as the high prevalence within 
African American communities. Currently, many treatment options exist, ranging 
from conservative treatments that address symptoms, to surgical intervention to 
remove the uterus. Research efforts thus far have determined the relationship 
between the role of estrogen in the growth of uterine leiomyomas (which has led 
to development of medications that target different approaches to estrogen 
synthesis) and its effects in the pathogenesis. Studies have shown that estrogen 
acts on estrogen receptor subtypes, ERa and ERb. This study examines the role 
of these two receptors in estrogenic effects, and how these effects relate to the 
development of uterine leiomyomas. Available research has shown that each 
receptor has its unique functions and impacts the growth of tumors differently. 
There is conflicting evidence in how the number of receptors and surrounding 
environment modulate leiomyomas, with some studies reporting that it is the 
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corepressors and/or coactivators that ultimately determine the influence of 
estrogenic effects. However, the general consensus of such studies suggests 
that estrogen receptor-specific therapeutic intervention is a novel area with great 
potential. The primary benefit of estrogen receptor-specific treatment, such as 
selective estrogen receptor modulators, is the ability to regulate physiological 
processes that contribute to the growth of uterine leiomyomas. Future directions 
of research include confirming the exact roles of ERa and ERb and harnessing 
the effects of their differing functions to manage uterine leiomyomas.  
 
Key Terms: estrogen, estrogen receptor alpha, estrogen receptor beta, uterine 
leiomyoma, receptor-mediated therapies, uterine fibroids 
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INTRODUCTION 
 
This thesis begins with a brief overview of uterine leiomyomas, their 
development, and public health implications. Next, the role of an important 
reproductive hormone and its receptor in the development of uterine leiomyomas 
is explored through a review of published literature. Focusing specifically on the 
impact of estrogen and its mechanism towards leiomyoma growth, this work will 
explore clinical management options of a condition for which there is currently no 
non-surgical cure. Recommendations for the direction of future research will be 
provided, as well as the presentation of novel approaches for the management of 
the condition.  
 
A Brief Overview of Uterine Leiomyomas 
Uterine leiomyomas, also known as uterine fibroids, are benign tumorous 
growths in the smooth muscle tissue of the uterus. Leiomyomas are the most 
common pelvic tumor affecting nearly twenty percent of women of childbearing 
age (Khan, 2014). While the tumors are normally asymptomatic, the foremost 
symptoms that may occur are abnormal uterine bleeding, urinary retention, and 
pelvic pressure. The exact etiology of leiomyomas is unknown, but there are 
many risk factors associated with their development, with greater incidence rates 
among Black populations. With a significant cost of treatment, an increasing 
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number of research efforts have been dedicated to isolating the cause and risk 
factors in an attempt to decrease the burden of the disease.  
 Uterine leiomyomas are a public health concern in part because of the 
high prevalence within Black women. High cost is associated with treatment, and 
loss of productivity also warrants public health concern in terms of discovering 
more efficient, and less burdensome, treatment options. For women between the 
ages 18 and 44, uterine leiomyomas account for nearly 47% of hysterectomies 
performed. Black women, specifically, are 2.4 times more likely to have a 
hysterectomy compared to White women (Stewart, 2013). In terms of costs for 
treatment, 4 to 10 billion dollars are spent annually, and an additional 1.5 to 17.2 
billion dollars are lost annually to missed work hours (Owen, 2015).  
Studies by Laughlin and Stewart (2011) on women between the ages of 
35 and 49 have shown that uterine fibroids in Black American women had an 
incidence of 60% by 35 years old, which increased to 80% by age 50. In contrast, 
White women had an incidence of 40% by age 35, increasing to 70% by age 50. 
Black women have been found to be two to three times more likely to develop 
fibroids, be diagnosed at a younger age, have seven or more fibroids, and have 
more severe symptoms. Black women are also two times more likely than White 
women to have a hysterectomy because of leiomyomas (Weiss, 2009). With 
these numbers in mind, researchers work to develop a social and historic context 
of uterine leiomyomas to determine the cause of this racial disparity.  
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 Studies have been performed elucidating the relationship between 
socioeconomics, race, and coping strategies. In a study conducted by 
Timmermans and Haas (2008) Black women were observed to minimalize the 
severity of their condition, even though Stewart et al. (2013.) explained that Black 
women significantly experience severe symptoms, such as heavy bleeding. 
Questioning the reason behind their sentiments, many reported in the 
Timmermans and Haas study that the inability to take time off from work was a 
major influencer. Some reported being socialized to be strong Black women and 
avoiding racial stereotypes in the workplace. Many participants were aware of the 
impact leiomyomas had on their quality of life, but adapted to the inconvenient 
symptoms by carrying emergency kits and reinforcements for bleeding. Health-
seeking behavior is an important contributor to the Black women’s experience 
with uterine fibroids. Interestingly, participants reported believing that 
leiomyomas developed as a result of genetics and the historical implications of 
being a Black woman in America. This belief is significant because the ways in 
which patients conceptualize their condition influence the treatments they pursue, 
with many concerned with preserving fertility.  
 
Physiological and Pathological Changes that Occur with Uterine 
Leiomyomas 
Uterine leiomyomas are composed of altered collagen fibrils, which cause 
rigidity in the myometrium. They are believed to be derived from the 
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transformation of myometrial connective tissue and smooth muscle cells into 
fibroblasts. They have also been found to contain altered cytokines and integrins 
due to tissue remodeling as well as inflammatory responses to fibroid 
development. Leiomyomas are typically found in a state of severe hypoxia, 
potentially resulting from abnormal angiogenesis as part of the inflammatory 
response (Owen, 2015).   
A study conducted by Ligon et al. (2002) on the monoclonal origins of 
uterine leiomyomas found that 40 to 50% harbor cytogenetic abnormalities 
usually on chromosomes 6, 7, 12, and 14. Karyotyping suggests the possibility of 
translocations, random X inactivation, inactivation of growth suppressors, and 
overexpression of genes promoting self-renewal. The cytogenetic abnormalities 
vary among patients and are differentially expressed by race, indicating a 
multifactorial causative agent.  
 
Figure 1 Masson Trichrome of Uterine Leiomyoma Uterine leiomyoma (a) compared to normal 
myometrium (b) with collagen fibers in blue and smooth muscle cells in red. Taken from 
Fernandes da Silva et al. (2016) 
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Figure 2 Histology of Uterine Leiomyoma. Hematoxylin and eosin stain of normal myometrium 
compared to a leiomyoma. Taken from Moravek et al. (2014) 
Uterine leiomyomas typically appear during a woman’s reproductive years, 
rarely occurring prior to menarche and regressing following menopause. The 
timing of the tumor development has piqued an interest in their development 
being influenced by steroid hormones (Wise, 2004). Estrogen and progesterone 
are the main ovarian steroid hormones synthesized during reproductive years. 
The smooth muscle tissues of uterine walls have receptors to these hormones, 
which are normally synthesized in synchrony with the ovarian and uterine cycles. 
Leiomyomas contain these receptors and have been found to have differential 
growth within different phases of the uterine cycle. Differential growth and 
shrinkage rates within the same woman were measured at consistent points 
within their cycle, and the results pointed to a multifactorial influence on growth.  
While the etiology of leiomyomas is still unknown, early menarche is 
associated with increased fibroid size, certain fibroid types, locations, and 
developing multiple leiomyomas as compared to women who had menarche after 
age 12 (Owen, 2015) They have also been found to be increased in groups with 
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high rates of obesity. In a retrospective cohort study by Shikora et al. (1991) it 
was observed that 50% of women with uterine fibroids were obese, with 16% 
being morbidly obese. This suggested a possible increased risk from certain 
diets. Dandolu et al. (2010) was also able to conclude that body mass index was 
a significant contributor to uterine weight. Other hypotheses for the cause of 
uterine leiomyomas indicate a link to growth factors during wound healing. 
Roeder et al. (2012) disclosed through a histopathological study that small 
fibroids developed within scar formation indicating alteration during wound 
healing. In the process of wound healing, angiogenesis restores blood flow to the 
damaged area. In leiomyomas, there is an increased expression of vascular 
endothelial growth factors (VEGF), a key regulator of angiogenesis. VEGF is in 
part regulated by estrogen and progesterone, providing further evidence of the 
correlation between steroid hormones and leiomyoma proliferation (Chegini, 
2010).  
Symptoms of leiomyomas depend on their location within the uterus. The 
most frequent symptoms are abnormal uterine bleeding, pelvic pressure, urinary 
incontinence, urinary retention, pelvic pain, and spontaneous miscarriage. 
Abnormal uterine bleeding results from obstruction of uterine vasculature that 
creates endometrial venule ectasia (Lockwood, 2011). The increased uterine 
bleeding is associated with increased risk of developing anemia from blood loss, 
producing symptoms such as fatigue. The pressure and pain are the result of the 
	 7	
size of the myomas, which increase abdominal girth and also produce urinary 
symptoms as a result of ureter compression. 
 Leiomyomas occur subserosally, submucosally, and intramurally. 
Subserosal tumors are just beneath the exterior lining of the uterine wall. 
Submucosal growths are beneath the mucosal layer, and intramural myomas are 
beneath the interior lining of the uterine wall. Subserosal and intramural fibroids 
are the most common found, accounting for 95% of reported leiomyomas. 
Subserosal tumors are usually asymptomatic and have no bearings on fertility, 
pregnancy, and birth outcomes compared to women without leiomyomas (Manta, 
2016). Women with submucosal or intramural tumors have lower clinical 
pregnancy rates, implantation rates, and higher rates of miscarriage. In regards 
to submucosal fibroids, once they are surgically removed, patients become 
asymptomatic and have comparable pregnancy successes in comparison to 
women without fibroids (Pritts, 2009).  
Pregnant women with uterine leiomyomas have increased risk of 
pregnancy-related complications. Women may experience bleeding in the first 
trimester, placental abruptions, and premature membrane ruptures. They also 
have increased risk of complications during labor and delivery, most commonly 
dysfunctional labor, prolonged labor, breeched positioning, pre-term delivery, and 
caesarean section. It was also observed that they had an increased risk for poor 
birth outcomes, decreased birth weight of newborns, and a decreased five 
minute Apgar score (Klatsky, 2008). 
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Since a majority of patients with uterine leiomyomas are asymptomatic, 
diagnosis usually results from pelvic exams during manual uterine palpations. 
Following the pelvic exam, ultrasounds are typically used to confirm the 
diagnosis. Transvaginal or abdominal ultrasounds are frequently used to detect 
tumors; however, they have limited ability to detect small tumors, making it 
difficult to identify fibroids at their onset. MRIs have better visualization, accuracy, 
and ability to map the exact location of small fibroids, but are used less frequently 
because of the cost (Lin, 2016). Cost of MRI’s can range from $1,000-$5,000 
whereas ultrasounds cost $100-$1,000 (Schwartz, 1994). Cost is a major 
deterrent in health-seeking behaviors and possibly contributes to the prevalence 
of uterine leiomyomas in Black women as compared to White women, who have 
stronger socioeconomic foundations.  
 
Figure 3 MRI of Uterine Leiomyoma. Shown compressing the bladder (A) and the spine (thin 
arrow) and colon (thick arrow) (B). Taken from Laughlin and Stewart (2011). 
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There are numerous options for the clinical management of uterine 
leiomyomas, ranging from conservative approaches that manage symptoms and 
preserve fertility, to approaches that eliminate symptoms but also eliminate 
fertility options. Pharmaceutical options for symptoms include NSAIDs to address 
pain from cramping and bleeding. Newer approaches include aromatase 
inhibitors, selective progesterone receptor modulators, selective estrogen 
receptor modulators and GnRH agonists. These methods aim to inhibit the 
influence of sex steroid hormones on the growth and proliferation of fibroids 
(Khan, 2014). Surgical options include myomectomies and hysterectomies. 
Hysterectomies are the only method to cure uterine leiomyomas, but 
simultaneously render the patient infertile. Myomectomies remove fibroids, and 
depending on the size and location can be done lapartomically, laparoscopically, 
or hysteroscopically. They allow for the uterus to be left in place and maintain 
fertility.  
Medical management approaches are gauged based on growth rate of 
existing myomas. In non-pregnant young women, or post-menopausal women 
with rapid growth, there is suspicion of malignancy and suggests surgical 
removal. Though it is rare that leiomyomas become cancerous, proactive 
removal is commonly performed as a cautionary measure. Once patients are 
found to have fibroids, they have serial follow-ups if they are small and not 
growing rapidly. Initially, these follow-ups occur every three months to establish 
growth intervals, and afterwards, follow-ups occur every four to six months. It is 
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important to have check-ins at a uniform time in a cycle in order to prevent 
erroneous conclusions on the growth and/or shrink rate of the fibroids. Initially, 
many physicians require follow-ups at three-month intervals in order to identify 
the tumors growth patterns. If the growth pattern is stationary, the intervals can 
be moved to four to six months (Wallach, 2004).  
 
Common Medical Management of Uterine Leiomyomas 
There are various medical options available in managing uterine 
leiomyoma, including both surgical and hormonal interventions. A myomectomy 
is the removal of a uterine fibroid while preserving the primary structure and 
function of the uterus. The surgery can be performed in three different ways: 
hysteroscopy, laparotomy, or laparoscopically. A myomectomy is the preferred 
surgical option for women who are considering having children. With advancing 
reproductive therapies available, women now have options and greater 
possibilities to conceive, and the preservation of the uterus is important in their 
decision to have a myomectomy (Wallach and Vlahos, 2004).  Determination of 
the efficacy of myomectomy is based on two important criteria: the position and 
size of the leiomyoma. A large fibroid (>3cm) may result in a uterus that is not 
functional after a myomectomy, unable to perform its reproductive responses 
such as maintaining the ovum and establishing a placenta. The position of the 
fibroid may also prove to be too risky to attempt to remove, due to apprehension 
of causing damage to nearby structures, such as the bowel and urinary tract. 
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Hysterectomy, surgical removal of the uterus, or a large part of it, is the 
second most frequent major surgery performed on women, following cesarean 
sections. This surgical option eliminates any possibility of recurrence, unlike 
myomectomy, which is not a solution to the underlying cause of leiomyoma. 
When symptomatic women are close to menopause and/or have fulfilled their 
desire to bear children, having a hysterectomy becomes an easier decision.  A 
hysterectomy offers the immediate relief of symptoms, including pain, bleeding, 
urinary tract symptoms, and pelvic pain (Rowe, 1999). Women are shown to be 
satisfied with their decision to have a hysterectomy because of symptom relief 
and believed to have better quality of life (Carlson et al., 1994). 
Hysterectomy is the only method of clinical management that completely 
cures women of uterine fibroids. However, surgical risk and the loss of a 
functioning uterus have expanded the search to find effective alternative 
treatments of uterine leiomyomas. Hormonal treatments have been developed in 
hopes of alleviating symptoms, reducing the volume of fibroids, and targeting the 
underlying cause of leiomyomas. Gonadotropin releasing hormone agonists are 
one venture into non-surgical treatment options. 
GnRH agonists work by increasing the release of gonadotropins. The 
drastic increase in gonadotropins causes the receptors to become desensitized. 
The ensuing downregulation creates a hypogonadotropic state that is similar to 
hormonal state during menopause. GnRH agonists have been clinically approved 
as a medical treatment that reduces the size of uterine leiomyomas and relieves 
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some of the symptoms in as early as the 4th week (Mizutani et al., 2005). 
However, the drawback to GnRH agonists is the drastic hypoestrogenic state that 
causes adverse effects, including osteoporosis (Stewart, 2001). It was also 
observed that once administration of GnRHa was discontinued, volume of the 
uterus began to increase, as it reverted back to developing its pathology. The 
need for safe and effective methods of treating uterine leiomyomas has elicited 
novel hormonal treatments that focus on one proven contributor to the 
development of uterine fibroids, for example, estrogen. 
Table 1 Common Medical Management of Uterine Leiomyomas As adapted from 
(http://www.fibroiddoc.com/treatment-options/) 
Treatment Type Target Advantages Disadvantages 
Myomectomy Surgical Uterine 
fibroid 
Symptom relief  
 
Removes 
problematic 
fibroids 
 
Preserves 
uterus for future 
pregnancies 
Recurrence 
 
Surgical risks  
Hysterectomy  Surgical Uterus No recurrence 
 
Symptom Relief 
 
Only known 
cure 
Highly invasive 
 
Loss of fertility 
 
Cost 
 
Recovery time 
GnRH Hormonal Gonadotropin 
releasing 
hormone 
receptors.  
Fibroid volume 
reduction 
 
Symptom relief 
 
No procedure  
 
Preserves uterus 
Risk of 
osteoporosis 
 
Recurrence  
 
Menopause 
symptoms 
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Importance of Estrogen in the Female Reproductive System 
Estrogen plays a vital role in the function of specific cells, tissues, and 
organs. It is primarily a growth hormone for the reproductive system, a trigger for 
ovulation, and also functions to maintain the development of oocytes. Estrogen is 
produced in the ovaries, adrenal glands, and placenta during pregnancy. As one 
of the most important reproductive hormones, it is required for maintenance of 
positive sexual and reproductive health (Simpson, 2003). Outside the 
reproductive system, estrogen also contributes to the synthesis of binding 
proteins, lipoproteins, and blood clotting proteins. There are three major and 
naturally occurring estrogens in women: estrone (E1), estradiol (E2), and estriol 
(E3). Estradiol is the most active and profound estrogen during reproductive 
years (Nelson and Bulun, 2001). For the purposes of this thesis, estrogen will be 
referring to E2, estradiol only.   
The effects of estrogen are mediated through nuclear receptors. As a 
nuclear hormone, estrogen’s mode of action in cells is regulation of transcription 
in the nucleus. The interaction of estrogen with its receptor causes the induction 
of mRNA, which results in distinct proteins to be synthesized by ribosomes. The 
proteins then produce the desired effects of estrogen on the cell (DeMayo et al. 
2002). Estrogen synthesis begins in the ovary’s theca cells where androgen 
precursors are synthesized from the steroid, cholesterol. The precursors are 
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converted to the final product, estrogen, in granulosa cells by the enzyme 
aromatase (Hojo et al 2011). 
 
Figure 4 Synthesis of Estrogen. Adapted from Hojo et al. (2011) 
 Estrogen levels peak during a woman’s reproductive years. Understanding 
the hypothalamic-pituitary-gonadal axis is important in assessing estrogen levels 
at any given time. Regulation of the axis impacts steroid-sensitive organs such 
as the uterus and works to maintain the homeostasis of body processes, 
including reproduction. The axis begins with the hypothalamus secreting GnRH, 
which binds to receptors on the anterior pituitary. The anterior pituitary releases 
LH and FSH into the blood. The hormones make their way to the ovaries and 
stimulate the production of estrogen and inhibin. Estrogen acts as a negative 
stimulus to the hypothalamus, and causes a decrease in the production of GnRH, 
Cholesterol
Pregnenolone
17a-Hydroxypregnenolone
Dehydroepiandrosterone
Androstenedione
Testosterone
Estrogen
	 15	
and thus, further production of estrogen (Plant, 2015). This complex interaction is 
the foundation of menarche and future menstrual cycles.  
During the menstrual cycle, specifically at the follicular phase, estrogen 
induces ovulation by causing a surge in luteinizing hormone. During the luteal 
phase, estrogen works to proliferate the uterus lining for implantation with the 
influence of progesterone (Gleicher, 2000). The menstrual cycle provides the 
resources necessary to restore and replenish the reproductive tract, in order to 
maintain the wellness of sexual and reproductive health. Estrogen levels 
experience a drastic decrease and production slows at perimenopause, which is 
considered to be months before a woman’s last period. After the onset of 
menopause, women will no longer menstruate, however there is still a small 
synthesis of estrogen in the ovaries. Low levels of estrogen are responsible for 
the hot flashes, sleep disturbances, and mood swings that encompass a 
woman’s experience postmenopause (Prior 2006).  
 
Figure 5 Estrogen Levels during a Women's Life Cycle Adapted from Prior (2006). 
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ERa and ERb 
The estrogen receptors are nuclear receptors that contain structurally and 
functionally distinct domains. The two estrogen receptors, ERa and ERb, have 
similar affinities for estrogen, bind the same DNA response elements, and have 
conserved sequence homology except in their N-terminal. The DNA-binding 
domain is responsible for DNA recognition and binding, and it is the most 
conserved area. The ligand-binding domain is multifunctional and occurs at the 
C-terminal. The N-terminal represents the most variable domain in both 
sequence and in length. Two activation functions, AF-1 and AF-2, assist 
transcriptional activation. AF-1 is continuously active and located at the N-
terminal while AF-2 is located at the C terminal and is ligand- dependent. Ligand-
dependent estrogen signaling is cell-specific and depends on the composition of 
coregulatory proteins in a given cell and signaling is initiated with the binding of 
estrogen to the receptors (Katzenellenbogen, 2000).  
It was initially believed that ERa was the only estrogen receptor that mediated 
the extensive effects of estrogen. PCR primers were used to clone ERb from 
humans and it was discovered that the ERa and ERb were encoded by and 
located on different genes, chromosome 6 and chromosome 14, respectively, 
indicating that they are both distinct receptors. The identification of ERb revealed 
the complexity of estrogen signaling. This discovery helped explain the estrogen 
action in tissues that do not express ERa. Due to the structure of the two 
receptors, they are observed to form heterodimers that have both similar and 
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distinct roles in estrogen-dependent action. Their different distributions contribute 
to differing actions in specific tissues (Dechering, 2000).  
When both ERa and ERb are expressed in cells, ERb can antagonize the 
transcription processes of ERa and inhibit the action of ERa. The mechanisms 
regulating the estrogen receptors, and interaction of ERa and ERb with each 
other present a means to understand estrogen-mediated processes in normal 
and pathological tissues. The role of estrogen in various cells is dictated by the 
structure of the ligand, the distribution and type of estrogen receptor, and the 
surrounding environment of coactivators and corepressors. Novel synthesis of 
estrogen receptor-specific agonists and antagonists will prove to be an important 
field of therapy (Katzenellenbogen, 2000).  
 
Figure 6 Schematic of structure and homology of ERa and ERb. The domains A-F and 
activation functions, AF-1 and AF-2, are shown. Adapted from Katzenellenbogen et al (2000).  
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SPECIFIC AIMS 
The specific aims of this thesis are:  
1. Indicate the importance of estrogen dependency on the growth of uterine 
fibroids. 
2. Examine the role of ERa and ERb. 
3. Examine the effects of receptor-mediated therapies. 
4. Recommend other areas of interest to address possible pathways for the 
disease.  
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PUBLISHED STUDIES  
 
Biological and Clinical Evidence Indicating Estrogen Dependency of 
Uterine Leiomyomas 
This section will focus on various biological and clinical trials involving 
treatment options that indicate a strong estrogen dependency on the growth and 
size of uterine leiomyomas. Proposed treatment options, such as aromatase 
inhibitors and gonadotropin releasing hormone agonists, are a few therapies 
used to decrease the amount of estrogen in the uterus that subsequently 
decreases the size of the fibroids. Many of these therapies are directed towards 
premenopausal women, who have high levels of estrogen due to the natural 
menstrual cycle, as compared to post-menopausal women, who have a 
significantly lower amount of estrogen.  
Marshall et al. (1998) determined through a prospective study that the 
incidence of uterine fibroids increased with early onset of menarche (£10) and 
those with late onset ( ³16) had a lower risk. Early onset menarche had a relative 
risk of 1.24 with a 95% confidence interval 1.08-1.4, whereas late onset 
menarche had a relative risk of 0.68 with a 95% confidence interval of 0.53-0.88. 
Wise et al. (2004) explained that early onset of menarche increased the risk of 
uterine fibroids because the myomas respond to estrogen, and their incidence 
parallels the development and changes in reproductive hormones. Early onset 
menarche leaves women with an increased number of ovulatory cycles. The 
	 20	
luteal phase is a stage of the menstrual cycle where the lining of the uterus 
thickens. More encounters with the luteal phase increases the risk of developing 
a fibroid.  
Uterine leiomyomas predominantly occur during premenopausal years, 
which indicates that estrogen plays an important role in its development because 
after the onset of menopause, estrogen levels dramatically decrease. 
Templeman et al. (2009) assessed the relative risk factors for pre-, peri-, and 
post-menopausal women. They determined that the relative risk was dramatically 
less for post-menopausal women (1.00) compared to pre (5.31, with a 95% 
confidence interval of 3.61-7.82). It was also found that perimenopause women 
had decreased risk than premenopausal women. During perimenopause, the 
body is approaching menopause and estrogen production decelerates, indicating 
the important role of estrogen.  
Templeman et al. (2009) also found that women who used hormone 
replacement therapy post-menopause had an increased relative risk compared to 
those who did not use HRT. Whether they used only estrogen, or a combined or 
mixed hormone therapy, the risk was greater (RR 2.03, 2.38, 3.25, respectively) 
than the relative risk of no HRT (1.00). The hormone therapy replenishes some 
of the estrogen that is lost with the onset of menopause. This could hinder the 
reduction of pre- and perimenopausal fibroids, which would otherwise shrink on 
their own post-menopause because of the lack of high levels of estrogen 
(Ciarmela et al. 2014).  
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Ishikawa et al.  observed that aromatase mRNA levels in leiomyoma 
tissues were strikingly higher compared to non-leiomyoma myometrium. This 
paralleled the increase in levels of estrogen within myomas, which indicates that 
myomas produce estrogen de novo as well as receiving the hormone from the 
ovaries. Furthermore, low levels of 17b-hydroxysteroid dehydrogenase have 
been found in myomas. 17b-hydroxysteroid dehydrogenase converts estradiol to 
estrone. Estradiol is the most active form of estrogen, whereas estrone has 
lesser effect (Reed et al. 1985). Without 17b-hydroxysteroid dehydrogenase, 
estradiol accumulates in the cells, and leads to up-regulation and hyper-
responsiveness to estrogen, resulting in myoma growth (Parker, 2007).  
Aromatization of androgens to estrogens is catalyzed by the cytochrome 
P450 enzyme, aromatase, specifically converting testosterone to estradiol and 
androstenedione to estrone. Aromatase’s structure contains a steroid-binding site 
and an iron-containing site. This sets up the potential for the enzyme to be 
inhibited by two methods: blocking the steroid-binding site or interfering with the 
iron-binding site (Fishman, 1982). Aromatase inhibitors are the ideal means to 
target estrogen because the aromatase enzyme catalyzes the final step in 
estrogen synthesis. This decreases the chance of affecting other cholesterol 
derived products, including cortisol and aldosterone (Murphy, 1998). 
Shozu et al. (2003) reported the first case of a premenopausal patient who 
used an aromatase inhibitor to manage a large uterine fibroid. The middle-aged 
woman began therapy with 2 mg of fadrozole, an aromatase inhibitor. Eight 
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weeks post onset of therapy, the volume of the large fibroid had decreased by 
71%. E2 levels had lowered to <10 pg/mL from the initial 80 pg/mL found in her 
serum upon first examination. At the conclusion of the treatment, there was no 
regrowth of the fibroid and her initial symptoms had ceased. Aromatase inhibitors 
suppress estrogen synthesis directly. The case report suggests that rapid 
decrease in serum levels of E2 decreased the patient’s symptoms and volume of 
the fibroid. It was reasonable to conclude the shrinkage of the fibroid was due to 
the decrease in estrogen.  
Maggiore et al. (2014) conducted a non-randomized comparative study 
where they secondarily evaluated the effect of an aromatase inhibitor, letrozole, 
on the size of uterine myomas prior to a myomectomy. This 80-patient study was 
divided into two groups: group A received the three-month treatment and group B 
did not. Total myoma volume was decreased (-41.2 ± 7.7%), which provided a 
significant decrease in the amount of time it took to complete the operation to 
remove the myomas. The study confirmed that letrozole is a safe therapy in 
reducing the size of uterine fibroids and showed that the blocking of estrogen can 
cut off the supply that allows fibroids to grow.  
Hilario et al. (2009) designed a clinical study to assess the role of 
aromatase inhibitors in the management of uterine leiomyomas size, symptoms, 
and serum levels of estradiol and FSH. Statistical analysis showed significant 
reduction in the volume of the uterine leiomyoma from T1 to T2 with aromatase 
inhibitor treatment. Although there was reduction in size, serum levels of estradiol 
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did not have a significant decrease, unlike what was presented in the studies 
evaluated by Shozu et al. (2003) and Maggiore (2014). There was still a 
decrease in the size of the fibroid even though hypoestrogenism was not present. 
They hypothesized that it was due to the low dosage of treatment that was 
unable to sufficiently block the synthesis of estradiol in the ovary. With an 
increased dosage, it is possible that the levels of estradiol would significantly 
decrease and have a greater impact on alleviating symptoms.  
Aromatase inhibitors are one important estrogen-suppressing treatment 
for uterine leiomyomas. While they directly inhibit the synthesis of estrogen, 
gonadotropin releasing hormone agonists work indirectly to create a state of 
hypoestrogenism in order to decrease the volume of uterine fibroids.  
Parsanezhad et al. (2010) compared the efficacy of aromatase inhibitors and 
GnRHa. They designed a randomized and controlled clinical trial where 60 
subjects that had a uterine leiomyoma greater than 5cm where randomized into 
group A and group B and completed the study. Group A received the aromatase 
inhibitor, letrozole, while group B received the GnRHa, triptorelin. Both groups 
had significant reduction in the size of the myoma. Group A decreased by 45.6% 
and group B decreased by 33.2% at the end of the 12 weeks of treatment. 
Chegini et al. (1996) described the role of GnRH in the development of 
leiomyomas and how GnRHa inhibits its mechanisms. GnRHa suppressed the 
rate of [3H] thymidine incorporated into myometrial smooth muscle cells, which is 
significantly stimulated in the presence of E2. Increased levels of [3H] thymidine 
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contributes to the proliferation of the smooth muscle cells and its response to 
GnRHa indicated that there are receptors present in myometrial smooth muscle 
cells that respond to GnRH. Chegini et al. (1996) provided the first data to 
indicate the direct action of GnRH in myometrial smooth muscle cells. This is a 
different perspective to the mode of action than those who focus on the indirect 
nature of GnRHa. GnRHa is more commonly known to downregulate the 
pituitary-ovarian-gonadal axis, which leads to the inhibition of estrogen 
production to levels similar to those measured during menopause (Beshay and 
Carr 2013). Cessation of GnRHa has resulted in an increase in leiomyoma 
volume as explained by Friedman (1993) and Broekman (1996). This again 
suggests that estrogen has a strong impact on the development of uterine 
leiomyomas, and indicates that there are possible novel avenues to treat 
estrogen levels.   
Mizutani et al. (2005) confirmed that GnRHa reduce the size of uterine 
fibroids by assessing the effects of three add-back therapies: CEE, MPA, and 
CEE plus MPA. The hypoestrogenism that GnRHa causes has been clinically 
shown to produce disorders, such as osteoporosis (Friedman, 1993). Fibroids 
were obtained from patients treated with GnRHa, GnRHa and an add-back 
therapy, and those who were not given any treatment. Mizutani et al. (2005) 
quantified the size of the leiomyoma by the number of Ki-67-positive leiomyoma 
cells/cm2, a marker for cell proliferation activity. GnRHa alone caused the biggest 
decrease in Ki-67-positive cells (30% at the end of the 4th week, and 14% by the 
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12th week). The add-back therapies were considered to have a possible benefit in 
preventing the development of adverse disorders, however, the reduction of Ki-
67-positive cells, and in relation, the size of the uterine leiomyomas, were not as 
significant had GnRHa been used alone. 
It is biologically and clinically confirmed that the development of uterine 
fibroids is estrogen dependent. Had it not been, therapies, such as aromatase 
inhibitors and gonadotropin releasing hormone agonists, would not be effective. 
However, these treatments have been able to reduce the volume of uterine 
myomas, alleviate symptoms, and also reduce operative time of removing the 
fibroids. The reduction of estrogen levels and subsequent shrinkage of the 
benign tumors confirm the role of estrogen in developing and maintaining the 
size of the fibroids. Continued exploration in endocrine therapy is an important 
effective way to treat conditions because it decreases the need to perform 
surgery. 
 
ERa and ERb role in Uterine Leiomyomas  
Despite research demonstrating a discernable role of ERa, ERb‘s 
influences on estrogen-dependent processes, the functions and growths have 
not been clarified. Several studies have indicated that in benign tumors, the ratio 
of ERa and ERb is higher compared to normal tissues. While ERa is shown to 
have a proliferative action in target tissues, ERb is hypothesized to be inhibitory 
to excess proliferation. The balance and influence of the two receptors on 
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estrogen maintenance and proliferation provide a point of research for receptor-
mediated therapies.  
Fuqua et al. (2003) created a monoclonal antibody to detect ERb at the 
protein level in breast cancer tissues in a study of 242 patients. Their results 
indicated that ERb was less significant in determining tumor grade and 
proliferation in comparison to ERa. ERb was only observed to have a correlation 
with aneuploidy. The rate of aneuploidy was greater in ERb -positive tumors than 
tumors that lack both ERa and ERb. This result indicated that ERb -positive 
tumors might be more assertive than others. In contrast, Park et al. (2003) used 
in situ hybridization of mRNA to compare ERb mRNA levels in varying breast 
tissue. It was discovered that ERb expression in metastatic lymph node tissues 
and breast cancer biopsies was decreased compared to those in normal 
mammary tissue. 
Similarly, Rutherford et al. (2000) assessed the expression of ERa and 
ERb mRNA and protein levels in normal ovarian and metastatic tumor biopsies. 
Western blot analysis was used to determine protein levels with the use of 
antibodies. Of the 25 participants, nine had normal biopsies, eight were of a 
primary tumor, and eight had a metastatic tumor. A primer was used to amplify 
the expression of ERa and ERb through a reverse transcriptase polymerase 
chain reaction and it was quantified. They found that amounts of ERa and ERb 
varied in the different types of biopsies. Normal ovaries had both ERa and ERb, 
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with ERb being greatly transcribed at a 1:2 ratio, which was determined by the 
mRNA and proteins present. Primary tumor biopsies were shown to have ERa in 
greater abundance, with drastically lower levels of ERb. In metastatic tumor 
biopsies, there was only ERa present. This suggested that ERa was responsible 
for the proliferation of undesired growth, and ERb provided inhibition to this 
process. 
Pujol et al. (1998) also determined that the ERa/ERb ratio increase was 
evident in ovarian cancers compared to normal ovaries and cysts. 60% of 
ovarian cancers were shown to have an ERa/ERb ratio of greater than one, and 
they showed that ERb was predominant in normal ovarian tissues. These 
findings resonate with those found by Rutherford et al. (2000), that ERa 
overexpression and/or loss of ERb contribute to tumorigenesis. ERa again is 
shown to have proliferative actions, while ERb is present to put a halt on excess 
growth. The balance between the two subtypes of the estrogen receptor is 
indicated to be essential in maintaining cellular homeostasis. 
There are few studies on knockout ERa or ERb receptors for uterine 
leiomyomas, but there are ample studies on breast cancer. Boccinfuso and 
Korach (1997) investigated the role of the estrogen/ER signaling pathway on the 
mammary development and tumorigenesis. The presence of ERa in both ductal 
epithelial cells and stromal cells revealed that there is a strong estrogen link in 
estrogen and mammary gland development, which was shown to secrete growth 
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factors in the presence of estrogen. They utilized a knockout study to understand 
the direct link between the estrogen receptor alpha and mammary development. 
The mammary oncogene Wnt-1 was included to assess how the tissue would 
respond when it lacked estrogen receptors. ERKO/Wnt-1 mice still developed 
mammary tumors, but had delayed onset. This suggests that while estrogen 
receptor knockouts cannot remove the carcinogenic effects of Wnt-1, they 
present an important role in the stimulation of tumorigenesis. 
Couse et al (1995) created a knockout study to investigate estrogen 
insensitivity in mice that lacked the estrogen receptor alpha gene. Reverse 
transcriptase PCR illustrated that no wild type ERa mRNA was observed after 
the gene knockout. Their study demonstrated that estrogen insensitivity was 
present in ERaKO mice, which was confirmed by increased estrogen levels in 
the serum, which increased ten-fold. The lack of response to estrogen treatment 
resulted in significantly decreased DNA synthesis, and transcription of 
downstream post-estrogen action genes. This indicates that the presence of the 
estrogen receptors is important for estrogen-mediated action.  
Couse et al. (1999) continued to explore the roles of ERa and ERb to 
understand how they affect target tissues. They found that mice homozygous for 
both receptor knockout, coined abERKO, created mice that had normal 
reproductive development, but were infertile, indicating the importance of the 
receptors for the ability to conceive. The abERKO phenotype suggests that both 
estrogen receptors are essential for ovarian function. Although the mechanism is 
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still unclear, Couse et al. attribute the loss of function to be influenced by 
elevated expression of the MIS gene, which has been observed in oocyte and 
granulosa cell death. 
Dupont et al. (2000) performed a knockout study on ERa and ERb on the 
reproductive phenotypes of mice. In order to create the ERa knockout, they 
altered exon 3, which encodes the first zinc finger of the DNA-binding domain. 
For ERb, they inserted the neo gene into the SpeI site of exon 3 through 
homologous recombination. They controlled these disruptions with 
immunohistochemistry, using staining to detect the signals of the different ERa, 
ERb, ERaKO, and ERbKO. Through this study Dupont et al. determined that with 
ERbKO the incomplete penetrance of weakened follicular growth indicated the 
existence of a partial functional compensation by ERa. They also showed that 
although ERa is the predominant estrogen receptor in the uterus, with an ERa 
knockout, ERb could possibly compensate for the loss of ERa. 
 Krege et al. (1998) also used the neo gene in exon 3 by homologous 
recombination to create phenotypic mice lacking the estrogen beta receptor. 
Their RNA analysis revealed that the tissues did not have functional ERb mRNA 
and proteins in mice that were ERb -/-. Development and functionality of the 
breasts were not affected by the absence of ERb, whereas mice lacking ERa 
were unable to develop breast tissue further than what had occurred prior to 
menarche. The urogenital and reproductive organs of the mice were functional 
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and normal in the ERb -/- mice. Krege et al. determined that ERa, rather than 
ERb, was the estrogen receptor subtype that was essential for normal growth 
and function. 
Jakimiuk et al. (2004) designed a prospective study to assess the 
differences of ERa and ERb expression in uterine leiomyomas and healthy 
myometrium. Sensitivity of leiomyomas to estrogen was shown to have a greater 
significance than increased expression. They observed that there was no 
significant difference between the expression of ERa and ERb in uterine 
leiomyomas compared to normal myometrium. This led to the conclusion that it 
was due to the sensitivity of the ER receptors, not the increased or decreased 
expression of the receptors, that influenced the development of uterine 
leiomyomas. 
However, Hall and McDonnell (1999) stated that although the sensitivity of 
the estrogen receptors plays a significant role in the development of uterine 
leiomyomas, the expression of the receptors is also a great influencer. They 
suggested that ERb is capable of regulating the transcriptional activity of ERa. 
They proposed the explanation that ERb can suppress ERa, because ERb can 
bind its response element in a constitutive way and challenge ERa for the access 
of the DNA target. The testing of Hall and McDonnell’s hypothesis revealed that 
ERb functions as a trans-dominant inhibitor of ERa transcriptional activity by 
decreasing the cells sensitivity to estrogen. Therefore, the expression of the 
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estrogen receptors sways the cellular response to estrogen, estrogen agonists, 
and estrogen antagonists. 
Bakas et al. (2008) utilized samples from biopsies of normal myometrial 
tissue and uterine fibroids to determine the DNA-binding status of ERa and ERb. 
They assessed whether increased level of estrogen receptors in leiomyoma was 
caused by increased gene expression of ERa and/or ERb and how it affected 
their binding to ERE. Bakas et al. accomplished this by using samples from 35 
women and revealed that the level of expression of ERa and ERb mRNA in 
leiomyomas were greater than levels found in normal myometrium, which 
resulted in higher levels of estrogen receptors. This increase in ERa in the 
leiomyoma allowed the receptor to bind to ERE as a homodimer and ERb as a 
heterodimer, a feat that is not seen in normal myometrium. Down-regulation of 
ERa in uterine leiomyomas is a potential therapy of their growth 
ERa was once thought to be the only type of estrogen receptor, however, 
presence of ERb indicates it physiologic role in uterine leiomyomas. Valladares 
et al. (2006) explored the cellular localization of the estrogen receptor subtypes 
in uterine leiomyomas with a retrospective study. ERa was observed to be 
present in only smooth muscle cells of the leiomyoma. ERb, on the other hand, 
was present in smooth muscle cells, connective tissue cells, and endothelial 
cells. Smooth muscle cells, connective tissues cells, and endothelial cells 
produce various factors, including VEGF. Valladeres et al. demonstrated that the 
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presence of factors regulated the estrogenic effects of ERa and ERb. ERb’s 
location in endothelial cells and connective tissue cells indicate that the factors 
produced in these cells specifically modulate ERb, since ERa is not present in 
these cells. They concluded that it is possible that ERb, and not ERa, is the 
major contributor to the development of uterine leiomyomas. 
Brandon et al. (1995) attempted to characterize the molecular 
mechanisms that are the basis for developing uterine leiomyomas. They 
suggested that overexpression of estrogen receptors results in increased 
sensitivity to estrogen and also caused increased expression of progesterone 
receptors in leiomyomas. Through Northern analysis, they showed that ER 
mRNA levels were increased from 1.4 to 12.6-fold in leiomyomas compared to 
healthy myometrium. Scatchard analysis determined that in leiomyomas, ER 
binding capacity to estrogen increased, but ER binding affinity was not 
significantly different from normal myometrium. This finding revealed that it is 
possibly the estrogen signal transduction pathway that may be more enhanced in 
uterine leiomyomas, which is a reasonable mechanism to account for the 
increased expression of progesterone receptors in leiomyomas. It is possible that 
leiomyomas autonomously increase expression of both estrogen and 
progesterone receptors. 
Glace et al. (2009) characterized the pharmacological regulation of 
stromal cell-derived factor-1 to determine its use as a biomarker for estrogenic 
effects. They explained that some pharmacological models used to determine 
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estrogenic activity are limited by the low throughput and lengthiness of treatment. 
They used microarray analysis to distinguish differences in gene expression in 
their rat analog. Glace et al. revealed that a rat leiomyoma cell line that lacked 
ERa did not have estrogen-dependent SDF-1 regulation, suggesting the roles of 
estrogen in regulated SDF-1 expression. After treatment with estrogen on 
functional ERa, the expression of SDF-1 increased. They were unable to confirm 
that SDF-1 played a significant role in proliferation, but they determined that 
SDF-1 gene regulation is conserved and could potentially be used as a 
biomarker. 
Shaik et al. (2011) explored the expression of ERa and mitochondrial 
cytochrome b (MTCYB) transcripts in premenopausal uterine leiomyomas. 
Estrogen was observed to stimulate the expression of mitochondrial genes. This 
study proposes that mitochondrial genes are important in leiomyomas. 
Overexpression in ERa and MTCYB transcripts were observed at 9.18 ± 0.79 
fold and 5.24 ± 0.48 fold, respectively, in uterine leiomyomas compared to 
normal myometrium. This increase was also correlated with the fact that 
leiomyomas with CC genotype had increased levels of ERa at 11.9 ± 1.02 fold. 
Increased transcript resulted in elevated ERa levels, which influence estrogenic 
activity. Their results suggested that the elevation of ERa and MTCYB transcript 
levels and its relationship with ERa, -397 CC genotype suggests the 
mitochondrial-mediated role of estrogen as an influencer of the progression of 
leiomyoma development. 
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Premenopausal leiomyomas have been observed to express higher levels 
of ERa and ERb than healthy myometrium. Strissel et al. (2007) assessed the 
expression of ERa and ERb in postmenopausal women. They evaluated a group 
of 14 postmenopausal patients using reverse transcriptase PCR and realtime 
PCR. Mean average results demonstrated that ERb was 2.5-fold overexpressed 
in postmenopausal women (p=0.038). ERa was not significantly different in 
postmenopausal leiomyomas compared to normal myometrium. This suggested 
that upregulation of ERb was evident at the transcriptional level and the actions 
of estrogen functioned predominantly in the ERb pathway compared to the ERA. 
Strissel et al. accounted for the increased expression of ERb as being 
responsible for growth suppression and maintenance. 
Sakaguchi et al. (2003) assessed the expression of ERa and ERb in 
premenopausal and postmenopausal myometrium. Competitive reverse 
transcriptase polymerase chain reaction-Southern blot analysis was used to 
quantify the levels of ERa and ERb. In premenopausal women, the ratio of ERb 
to ERa was evaluated to be 0.6-1.5, signifying the presence of more ERa than 
ERb. In contrast, for postmenopause women, the ratio was determined to be 2.5-
7.6. This suggested that between premenopause to postmenopause, there was a 
change in the ratio of ERb to ERa. Administration of estrogen was shown to 
change the ERb to ERa ratio in postmenopausal women to that of 
premenopausal women.  
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Sakaguchi et al. also showed that in premenopausal women, GnRHa 
decreased expression of ERa to levels similar to postmenopausal women, but 
increased ERb expression greater than that found in postmenopausal women. 
Relative scores of Western blotting for premenopausal women were (183 ± 49) in 
ERa pre-treatment with GnRHa. After treatment, the relative scores were (122 ± 
36). WS values for ERb were 14 ± 13 and increased to (82 ± 27). For 
postmenopausal women, ERa WS values were (110 ± 26) to (197 ± 34) post-
treatment and ERb was (86 ± 22) to (37 ± 17). Overall, GnRHa increased the 
ratio of ERb expression to ERa expression. 
Shao et al. (2015) assess the expression of ERa and ERb in solitary and 
multiple uterine leiomyomas, indicating a possible correlation between estrogen 
receptor subtypes and the subtypes of leiomyomas. They used ELISA assay to 
quantify estrogen concentration, realtime PCR was used for mRNA expression of 
both receptors, and Western blot was used for detection of ERa and ERb protein 
expression. They observed that ERb mRNA and protein levels in multiple 
leiomyomas were significantly greater than those in solitary growths. However, 
ERa mRNA and protein levels in multiple leiomyomas were lower than those in 
singular leiomyomas. High ERb and lower ERa was characteristic of multiple 
leiomyomas compared to solitary tumors. In both solitary and multiple 
leiomyomas, ERa expression was greater than ERb and the concentration of 
estrogen was dependent on ERa expression.  
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Studies Concerning Therapies to Remediate the Effects of ERα and ERβ 
Selective estrogen receptor modulators (SERMs) are non-steroidal 
compounds that act on estrogen receptors as either agonists or antagonists. The 
most commonly used SERMs are tamoxifen and raloxifene. In different tissues of 
the body, they can have a stimulatory or inhibitory effect, with varying sensitivity. 
They are used for estrogen-responsive cancers, such as breast cancer. The 
ability for SERMs to have an antiestrogenic effect on estrogen receptors led to 
the development of a SERMs to manage uterine fibroids (Lethaby, 2008).  
Due to the fact that SERMs can have different actions in target tissues, 
the complete molecular network it is of great importance. The number of 
coactivators and corepressors influence the effect of SERMs through the 
estrogen receptor complex. Some coactivators are ubiquitous and can amplify 
the stimulatory action of the estrogen receptor complex by altering the genes 
involved in the ligand-activated initiation. A tissue site that contains more 
coactivators or less corepressors will more likely be an estrogenic site, and the 
opposite is true for anti-estrogenic sites (Lonard, 2006).  
SERMs act on the two estrogen receptors, ERα and ERβ after diffusing 
into cells. The receptors experience conformational and structural changes that 
allows them to interact with estrogen response elements, which results in specific 
estrogen effects. The ratio of ERα and ERβ plays an important role in the anti- 
and estrogenic effects of SERMs. Roger et al. (2001) observed that a low 
ERα/ERβ had protective effects on cell proliferation. Higher levels of ERβ 
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correlated with low levels of Ki67 (r 0.333). In contrast, a high ratio ERα/ERβ 
proved to have a proliferative response. This observation provides insight in 
assigning SERM antiestrogen preventative therapy for individualized treatment.  
One class of SERMs, tamoxifen, is an antiestrogenic drug used to treat 
breast cancer. Powles et al. (2007) demonstrated that tamoxifen was successful 
in reducing the risk of developing an ER-positive breast cancer through their 8-
year study of assigning the drug versus a placebo in almost 2500 women. They 
divided the participants in half, those who received tamoxifen, and those who 
received the placebo, and discovered that posttreatment, those with tamoxifen 
had less of a risk with a hazard ratio of .048 at a 95% confidence interval. Cuzick 
et al. (2007) also noted that while there was a significant decrease in breast 
cancer risk with tamoxifen, this reduction was only seen in ER-positive cancers. 
There was no significant reduction in ER-negative cancers. Tamoxifen was able 
to have success in creating an antiestrogenic effect on breast cancer cells, 
however, it is not used for the treatment of uterine leiomyomas because it has a 
risk of causing endometrial carcinoma. Therefore, there were no randomized 
control trials on uterine leiomyomas because of the adverse effects. 
 Raloxifene is another member of approved SERM that has been shown to 
have antiestrogenic actions on uterine leiomyomas. Unlike tamoxifen, it does not 
have the adverse side effects of osteoporosis, thrombolytic events, and 
endometrial carcinoma. Vogel et al (2006) conducted a study to compare the 
effectiveness of both tamoxifen and raloxifene in their ability to reduce ER-
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positive breast cancer risk. Their results concluded that raloxifene was just as 
effective as tamoxifen on the risk reduction of invasive breast cancer. They also 
discovered that those who received tamoxifen treatment developed endometrial 
hyperplasia, a precursor to endometrial cancer, more commonly than those 
receiving raloxifene. There was also a downward trend of uterine cancer 
incidence in the raloxifene group. Raloxifene was observed to be a less toxic and 
therefore a safer option in comparison to tamoxifen for treating invasive breast 
cancer.  
Palomba et al. (2001) designed a randomized, double blind, placebo-
controlled study to assess the effectiveness of raloxifene on the size of uterine 
leiomyomas. 70 women were split into those who received 60 mg/day of the 
treatment and those who received the placebo. 28 cycles of treatment were 
given, and during the early cycles, no significant variations were observed with 
the two groups. Six cycles in to the study, fibroid size had decreased with 
raloxifene. They determined that in postmenopausal women, raloxifene was 
successful in reducing the size of uterine leiomyomas. However, mean E2 levels 
of the subjects were greater in those who were receiving the treatment compared 
to those who were receiving the placebo (11.4 ± 4.8 vs. 10.9 ± 4.6).  Palomba et 
al. attributed this to the fact that there are ERα variants that lack E2 binding sites 
or the incorrect translation of ERα mRNA. 
Raloxifene has been approved to successfully reduce uterine leiomyomas 
in postmenopausal women. Jirecek et al. (2004) assessed raloxifene’s success 
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in middle aged premenopausal women after three months of treatment. Of the 25 
patients in the study, 13 received raloxifene treatment and 12 were the control 
group. Raloxifene was shown to induce a 22.2% decrease in the volume of 
leiomyomas after 3 months. Those on the raloxifene treatment had a baseline 
value of 59.0 ± 48.1 and their end point values were 54.4 ± 47.9. This reduction 
was in stark contrast with the control group, who had a baseline of 68.1 ± 48.0 
and end values of 78.4 ± 62.3, an increase in size. They determined that high-
dose raloxifene was effective in inhibiting the development of uterine 
leiomyomas. Importantly, raloxifene was also clinically tolerated with limited 
adverse side effects. 
Palomba et al. (2004) provided an evaluation of the effectiveness of 
combining raloxifene with a GnRHa as an add-back treatment. They discovered 
that after six months, there was a significant decrease in leiomyoma compared to 
the baseline. Clinically, the treatment was tolerated by the premenopausal 
patients. There was evidence of decreased bleeding observed with patients as 
treatment cycles progressed. Their data also indicated that raloxifene was able to 
protect patients from risk of osteoporosis and hypoestrogenic side effects of 
GnRHa. Raloxifene as an add-back therapy to GnRHa was determined to be a 
safe and effective method to manage uterine leiomyomas and continuation of the 
treatment continued to suppress the size of the leiomyoma.    
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DISCUSSION 
 
Estrogen has been confirmed to influence the development of uterine 
leiomyomas. This dependency is observed naturally between premenopausal 
and postmenopausal women (Templeman et al., 2009). Postmenopausal women 
are reported to have less incidence of uterine fibroids because estrogen levels 
drop drastically at menopause. Early onset of menarche led to increased 
susceptibility to uterine fibroids because of prolonged elevated estrogen 
exposure and the proliferation stage of the menstrual cycle (Marshall et al., 
1998).  
Pharmacological manipulation of estrogen levels also demonstrated the 
importance of the hormone on uterine fibroid growth. For example, hormone 
replacement therapy after menopause was shown to increase risk of uterine 
fibroids because it raised the levels of estrogen in women (Templeman et al., 
2009). While HRT was administered to increase estrogen levels, aromatase 
inhibitors and GnRH agonists were provided to premenopausal women to reduce 
estrogen levels. They were both shown to be effective in reducing estrogenic 
effects and the volume of uterine leiomyomas (Shozu et al., 2003, Maggiore et 
al., 2014, Chegini et al., 1996, Mizutani et al., 2005). However, with aromatase 
inhibitors and GnRH agonists, there is the risk of creating a hypoestrogenic state 
that have adverse side effects, including osteoporosis and symptoms associated 
with menopause.  
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The mechanism of how estrogen relays its effects on uterine growth is still 
unclear, however it has been validated that estrogenic effects are mediated by 
the estrogen receptors alpha and beta. The activation of estrogen receptors 
results in the subsequent activation of other genes through estrogen response 
elements and the production of growth factors. The estrogen receptors were 
shown to elevate the SDF-1 gene and MTCYB transcripts (Glace et al., 2009, 
Shaik et al., 2011). While the estrogen receptors are important in the 
development of aberrant growths, it was observed that its inhibition did not 
completely block the initiation of growths, but rather delays the promotion of 
growth (Boccinfuso and Korach, 1997). 
Of the two known subtypes of estrogen receptor, ERa and ERb, ERa has 
a more clarified role. ERa has been confirmed to be essential for regulated 
growth. Knockout studies have shown that ERa has a proliferative action in 
target tissues (Krege et al., 1998) with tumors having a greater transcription of 
ERa (Rutherford et al., 2000). ERb’s role is less clear, but it is hypothesized to 
impede excess proliferation. ERb was observed to be greater in normal tissue, 
indicating that it plays a role in maintaining the level of growth in a tissue and 
preventing abnormal growth (Pujol et al., 1998). However, ERb was also seen to 
compensate for ERa after it had been knocked out (Dupont et al., 2000), offering 
a unique, yet vague understanding of multifunctional role of ERb.  
With the opposing effects of ERa and ERb, some researchers have 
attempted to elucidate which receptor plays the greatest role in the development 
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of uterine leiomyomas. ERa is present in smooth muscles cells, however, ERb is 
present in smooth muscle cells, connective tissue cells, and endothelial cells 
(Valladares et al., 2006) indicating a vaster influence. There is an alteration of 
ERa/ERb ratio in uterine leiomyomas compared to normal myometrium. ERa in 
premenopausal women have more significant elevation in uterine leiomyomas 
than the increase in ERb transcript (Strissel et al., 2007). In postmenopausal 
women, ERb has a more significant flux of transcription. ERb elevation is 
observed in leiomyomas, compared to premenopausal women who have less 
ERb in uterine leiomyomas. This increase is caused by upregulation in order to 
maintain the development of the growths (Sakaguchi et al., 2002). Therefore, 
depending on the status of the woman’s reproductive age, there are different 
possibilities to modulate the receptors to manage uterine leiomyomas. A ERb 
agonist could be used to increase ERb transcript to inhibit the growth of uterine 
leiomyomas, or an ERa antagonist could be administered to block the role of 
ERa and its promotion of proliferation.  
Selective estrogen receptor modulators have immense potential for future 
research. They have been confirmed to decrease the volume of uterine 
leiomyomas. The ratio of ERα to ERβ needs to be assessed in order to 
determine which SERM is best to use, antagonist or agonist (Roger et al., 2001). 
Characterization of the estrogen receptor ratio provides insight on the 
coregulatory molecules present, which will modulate the ER-SERM complex 
(Lonard, 2006). Tamoxifen, for example, recruits corepressors and if they are low 
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in a particular fibroid, tamoxifen will not be able to produce its targeted effects. 
Tamoxifen has also been reported to have severe adverse effects, including 
hypoestrogenic-induced osteoporosis and thrombolytic events. Building on the 
development of raloxifene, synthesis of novel SERMs is an important approach 
for future research of uterine leiomyomas.  
The developing molecular and physiological understanding of estrogen 
and its receptors alpha and beta can be further exploited to design effective 
treatment of uterine leiomyomas. Using a combination of pharmacological 
treatments could potentially be effective in managing uterine leiomyomas. Using 
aromatase inhibitors to block the synthesis of estrogen and using SERMs to 
target the estrogen receptors would be very effective in ceasing the estrogenic 
effects on uterine leiomyomas. However, this will probably cause a 
hypoestrogenic state that is observed with GnRHa treatment because estrogen is 
a vast and ubiquitous hormone. The knock out studies performed by researchers 
highlighted another area of interest, gene therapy. Gene therapy, such as 
CRISPR, could be used to alter the transcript of ERα and ERβ and modulate the 
estrogenic effects of estrogen-dependent uterine leiomyomas.    
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CONCLUSION 
 
Endocrine manipulations are one of the least toxic therapeutic 
interventions for hormone-responsive conditions and present a growing field of 
medical research. It is clear that ERa and ERb play an important role in the 
development of uterine leiomyomas although their complexities have yet to be 
fully understood. Future research on estrogen and uterine leiomyomas should 
focus on characterizing and enhancing the value of ERa and ERb’s unique 
function in order to synthesize individualized selective estrogen receptor 
modulators. With ERa possibly contributing to proliferation and ERb inhibiting 
excess growth, there is opportunity to design a treatment plan catered to a 
patients tumor environment. Estrogen receptor agonists could be therapeutic for 
patients who have a low ERa/ERb ratio and abundance of corepressors. 
Antagonists would be beneficial for those who have high ERa/ERb ratio with an 
analysis of the complete molecular network of the leiomyoma.  
With current research, physicians can mediate symptoms in 
premenopausal and postmenopausal women. Using a combination of clinical 
management approaches can be beneficial, including using SERMs in 
conjunction with surgical treatments. SERMs could reduce the volume of the 
uterine leiomyoma, which would decrease risk and surgical-time frame 
associated myomectomies. Patients could also opt for a combination of two non-
surgical interventions, such as GnRH agonists with SERMs. While monitoring the 
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adverse of GnRHa, including hypoestrogenism, SERMs could contribute to 
volume reduction of uterine leiomyomas.  
Estrogen’s role in physiology has resulted in the development of relatively 
safe and effective treatments that target uterine leiomyomas. The benefits of 
non-surgical treatments are vast. These treatment options offer a less expensive 
and less invasive approach to manage uterine leiomyomas. However, further 
research must occur in order to access the full potential of endocrine modulation 
of the tumors. Targeting ERa and ERb as a means to treat uterine leiomyomas 
can bring medicine a step closer to developing a non-surgical cure and can be 
applied to other endocrine-sensitive conditions, such as breast cancer. 
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